Showing 21 - 40 results of 224 for search 'Vital Signs 1', query time: 0.07s Refine Results
  1. 21
  2. 22

    Effect of yoga exercises on lung volumes, vital capacity, and attention span in school going students by Reema Joshi, Manisha Rathi, Komal Preet Kaur

    Published 2024-12-01
    “…At the end of the 4 weeks, post-assessment of both the groups was assessed, documented, and statistically analysed using Wilcoxon signed rank and Mann–Whitney U -tests. Results Respiratory parameters (FEV1, FVC/FEV1, and PEFR), chest expansion, and the attention span of group A were statistically significant compared to group B with a p -value < 0.05. …”
    Get full text
    Article
  3. 23
  4. 24
  5. 25
  6. 26

    LOW TEMPERATURE STORAGE OF ACTINOBACILLUS PLEUROPNEUMONIAE CULTURES by V. S. Rusaleyev, D. A. Vasilyev

    Published 2018-04-01
    “…Basic tasks during storage of any microorganism cultures including Actinobacillus pleuropneumoniae involve maintenance of their vitality and stable taxonomically relevant signs. In different collections the microorganism vitality is mainly maintained using the following methods: repeated passages, lyophilisation and storage with mineral oil at low and ultra low temperatures. …”
    Get full text
    Article
  7. 27

    Value of Plasma NGAL and Creatinine on First Day of Admission in the Diagnosis of Cardiorenal Syndrome Type 1 by Hao Phan Thai, Bao Hoang Bui, Tien Hoang Anh, Minh Huynh Van

    Published 2020-01-01
    “…There were no significant differences of vital signs at admission, diagnosis, and EF-based heart failure between CRS1 and non-CRS1 groups. …”
    Get full text
    Article
  8. 28

    Continuous Patient-Independent Estimation of Respiratory Rate and Blood Pressure Using Robust Spectro-Temporal Features Derived From Photoplethysmogram Only by Muhammad Ahmad Sultan, Wala Saadeh

    Published 2024-01-01
    “…<italic>Objective:</italic> A patient-independent approach for continuous estimation of vital signs using robust spectro-temporal features derived from only photoplethysmogram (PPG) signal. …”
    Get full text
    Article
  9. 29

    Effectiveness of syndecan-1 as an adjunct diagnostic marker in small bowel injury: a report of two cases by Hideshi Okada, Keiko Suzuki, Fuminori Yamaji, Tetsuya Fukuta, Masahiro Ichihashi, Yosuke Mizuno, Takahito Miyake, Norihide Kanda

    Published 2025-01-01
    “…Trauma can damage the vascular endothelial glycocalyx, with syndecan-1 emerging as a marker of injury. Here, we describe two cases of small bowel injury due to traffic motor vehicle crash trauma.Case presentation The patients, one in their 40s and one teenaged, were transported to our hospital after a traffic motor vehicle crash. …”
    Get full text
    Article
  10. 30

    A phase I, randomized, placebo‐controlled trial to evaluate the pharmacokinetics, safety, and tolerability of nirsevimab in healthy Chinese adults by Xiaomeng Mao, Xiaohan Hua, Chengyi Wu, Xiaoyun Ge, Jie Zhang, Xiaojie Wu, Robert J. Kubiak, Ulrika Wählby Hamrén, Tonya Villafana, Georgios Christou, Jannine Green, Therese Takas, Yuwen Jin

    Published 2025-01-01
    “…Treatment emergent adverse events (AEs), clinical laboratory data, and vital signs were evaluated. Overall, 24 participants were randomized to nirsevimab (n = 18) or placebo (n = 6). …”
    Get full text
    Article
  11. 31

    Inhibiting the alternative pathway of complement by reducing systemic complement factor B: Randomized, double-blind, placebo-controlled phase 1 studies with Sefaxersen by Michael L. McCaleb, Steven G. Hughes, Tamar R. Grossman, Ashley Frazer-Abel, Bill Jung, Lixuan Yin, Scott P. Henry, Brett P. Monia, Eugene Schneider, Richard Geary, Gary T. Brice

    Published 2025-03-01
    “…All subjects (54) completed the studies and no safety signals or clinically meaningful changes in blood chemistry, urinalysis, hematology, ECG, vital signs or ocular endpoints were observed. Mean levels of systemic complement factor B (FB) were reduced up to 38 % after single administration and 69 % after repeated administration. …”
    Get full text
    Article
  12. 32
  13. 33

    Safety and Intranasal Retention of a Broad-Spectrum Anti-SARS-CoV-2 Monoclonal Antibody SA55 Nasal Spray in Healthy Volunteers: A Phase I Clinical Trial by Chaoying Hu, Yibo Zhou, Xing Meng, Jianhua Li, Jinxia Chen, Zhifang Ying, Xiaoliang Sunney Xie, Yaling Hu, Yunlong Cao, Ronghua Jin

    Published 2024-12-01
    “…The severity of adverse reactions (ADRs) reported during the study was mild in all cases, and all ADRs were laboratory test abnormalities without corresponding symptoms or vital signs. A total of 9 ADRs were reported, of which all were mild in severity. …”
    Get full text
    Article
  14. 34
  15. 35
  16. 36
  17. 37
  18. 38
  19. 39
  20. 40